We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-11.31%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$957M
AUM Growth
-$152M
Cap. Flow
+$41.2M
Cap. Flow %
4.3%
Top 10 Hldgs %
58.48%
Holding
65
New
21
Increased
9
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$47.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$26.3M
3
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$17.1M
5
ANAB icon
AnaptysBio
ANAB
+$16.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.4M
2
KYNB
Kyntra Bio
KYNB
+$24.3M
3
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$13.4M
4
SAGE
Sage Therapeutics
SAGE
+$12.5M
5
KURA icon
Kura Oncology
KURA
+$8.36M

Sector Composition

Rank Sector Weight
1 Healthcare 92.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
26
Ionis Pharmaceuticals
IONS
$8.93B
$9.86M 1.03%
+208,609
New +$11.6M
VIR icon
27
Vir Biotechnology
VIR
$1.46B
$9.27M 0.97%
+270,418
New +$7.27M
TCRT icon
28
Alaunos Therapeutics
TCRT
$4.64M
$9.19M 0.96%
+25,000
New +$12.9M
VSTM icon
29
Verastem
VSTM
$528M
$8.6M 0.9%
+271,318
New +$6.8M
BMY.RT
30
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$8.54M 0.89%
+2,248,300
New +$7.41M
CYCN icon
31
Cyclerion Therapeutics
CYCN
$15.2M
$7.27M 0.76%
137,114
+46,564
+51% +$3.32M
CHMA
32
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.52M 0.58%
1,512,627
-1,531,200
-50% -$6.79M
CRNX icon
33
Crinetics Pharmaceuticals
CRNX
$8.88B
$5.14M 0.54%
+350,000
New +$7.17M
XCUR icon
34
Exicure
XCUR
$11M
$4.21M 0.44%
18,942
-4,686
-20% -$1.48M
RCUS icon
35
Arcus Biosciences
RCUS
$3.33B
$4.05M 0.42%
292,100
-437,805
-60% -$5.44M
SVRA icon
36
Savara
SVRA
$1.08B
$3.04M 0.32%
1,432,664
– –
LSACU
37
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$3M 0.31%
+300,000
New +$2.97M
SURF
38
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$2.38M 0.25%
1,274,463
-27,250
-2% -$71.8K
ACRS icon
39
Aclaris Therapeutics
ACRS
$715M
$2.17M 0.23%
2,087,312
– –
CRVS icon
40
Corvus Pharmaceuticals
CRVS
$1.1B
$1.56M 0.16%
737,612
– –
ZYME icon
41
Zymeworks
ZYME
$1.62B
$1.47M 0.15%
+41,407
New +$1.69M
CRSP icon
42
CRISPR Therapeutics
CRSP
$4.69B
$1.29M 0.14%
+30,510
New +$1.58M
MGTX icon
43
MeiraGTx Holdings
MGTX
$1.08B
$1.27M 0.13%
+94,819
New +$1.6M
TRIL
44
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.18M 0.12%
+291,997
New +$1.1M
XOMA
45
DELISTED
Xoma
XOMA
$1.03M 0.11%
+50,809
New +$1.17M
RGLS
46
DELISTED
Regulus Therapeutics
RGLS
$870K 0.09%
+188,681
New +$1.65M
BPMC
47
DELISTED
Blueprint Medicines
BPMC
$816K 0.09%
+13,946
New +$897K
PVLA
48
Palvella Therapeutics
PVLA
$2.05B
$602K 0.06%
3,302
-28,388
-90% -$7.15M
FPRX
49
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$581K 0.06%
+256,075
New +$1.09M
EXEL icon
50
Exelixis
EXEL
$13.9B
$108K 0.01%
+6,269
New +$115K
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2020 Portfolio in Review

As of Q1 2020, EcoR1 Capital held 65 positions worth $957M, down 14% from $1.11B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

EcoR1 Capital deployed $41.2M of net new capital in Q1 2020, opening 21 new positions and adding to 9 existing holdings. Its largest new stake was Puma Biotechnology: 2,536,156 shares worth $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier.

On the sell side, the largest reduction was Kyntra Bio, an estimated $24.3M trimmed.

  • EcoR1 Capital's largest Q1 2020 buy was Puma Biotechnology: 2,536,156 shares worth $21.4M.
  • EcoR1 Capital added most to Fate Therapeutics in Q1 2020, an estimated $47.8M increase.
  • EcoR1 Capital's biggest Q1 2020 reduction was Kyntra Bio, cutting an estimated $24.3M.
  • EcoR1 Capital fully exited argenx in Q1 2020, selling an estimated $32.4M.
  • EcoR1 Capital's ten largest holdings make up 58% of its $957M portfolio in Q1 2020.
  • EcoR1 Capital opened 21 new positions and closed 14 in Q1 2020.
  • EcoR1 Capital's portfolio value fell 14% quarter-over-quarter to $957M.

Based on EcoR1 Capital's 13F filing for Q1 2020, filed 15 May 2020.